Federal contract award
75A50119C00022
ADVANCED RESEARCH AND DEVELOPMENT OF RVSV-MARV VACCINE.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $89.0M |
| Current contract value | $89.0M |
| Potential contract value / ceiling | $118.9M |
| Start date | Feb 1, 2019 |
| Current end date | Jan 31, 2029 |
| Potential end date | Jan 31, 2029 |
| Latest award activity | Jun 8, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 27 of 27 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jun 8, 2026 | P00026 | $33.5M | THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE OPTION 6. |
| Jan 16, 2026 | P00025 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO CORRECT THE PERIOD OF PERFORMANCE FOR CLIN0004/OPTION 3 TO APRIL 30, 2026, TO ALIGN WITH IPP. |
| Sep 24, 2025 | P00024 | $19.5M | THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE AND FULLY FUND OPTION 4/CLIN00005 |
| Mar 11, 2025 | P00023 | $0 | ADVANCED RESEARCH AND DEVELOPMENT OF RVSV-MARV VACCINE. - UPDATE POP |
| Nov 18, 2024 | P00022 | $0 | ADVANCED RESEARCH AND DEVELOPMENT OF RVSV-MARV VACCINE. - ADMIN MOD |
| Sep 25, 2024 | P00021 | $7.5M | ADVANCED RESEARCH AND DEVELOPMENT OF RVSV-MARV VACCINE. - SUPPLEMENTAL FUNDING MOD |
| May 28, 2024 | P00020 | $0 | ADVANCED RESEARCH AND DEVELOPMENT OF RVSV-MARV VACCINE. |
| Feb 29, 2024 | P00019 | $0 | ADVANCED RESEARCH AND DEVELOPMENT OF RVSV-MARV VACCINE. |
| Dec 13, 2023 | P00018 | $0 | ADVANCED RESEARCH AND DEVELOPMENT OF RVSV-MARV VACCINE. |
| Nov 2, 2023 | P00017 | $0 | ADVANCED RESEARCH AND DEVELOPMENT OF RVSV-MARV VACCINE. |
| Sep 21, 2023 | P00016 | $5.8M | ADVANCED RESEARCH AND DEVELOPMENT OF RVSV-MARV VACCINE. |
| Apr 25, 2023 | P00015 | $0 | ADVANCED RESEARCH AND DEVELOPMENT OF RVSV-MARV VACCINE. |
| Mar 21, 2023 | P00014 | $0 | ADVANCED RESEARCH AND DEVELOPMENT OF RVSV-MARV VACCINE. |
| Aug 4, 2022 | P00013 | $0 | ADVANCED RESEARCH AND DEVELOPMENT OF RVSV-MARV VACCINE. |
| Jul 22, 2022 | P00012 | $230.1K | ADVANCED RESEARCH AND DEVELOPMENT OF RVSV-MARV VACCINE. |
| Dec 6, 2021 | P00011 | $243.0K | ADVANCED RESEARCH AND DEVELOPMENT OF RVSV-MARV VACCINE. |
| Nov 2, 2021 | P00010 | $0 | ADVANCED RESEARCH AND DEVELOPMENT OF RVSV-MARV VACCINE. |
| May 26, 2021 | P00009 | $0 | ADVANCED RESEARCH AND DEVELOPMENT OF RVSV-MARV VACCINE. |
| Mar 18, 2021 | P00008 | $12.3M | ADVANCED RESEARCH AND DEVELOPMENT OF RVSV-MARV VACCINE. |
| Jan 19, 2021 | P00007 | $0 | ADVANCED RESEARCH AND DEVELOPMENT OF RVSV-MARV VACCINE. |
| Oct 6, 2020 | P00006 | $0 | ADVANCED RESEARCH AND DEVELOPMENT OF RVSV-MARV VACCINE. |
| Jul 13, 2020 | P00005 | $0 | ADVANCED RESEARCH AND DEVELOPMENT OF RVSV-MARV VACCINE. |
| Apr 27, 2020 | P00004 | $0 | ADVANCED RESEARCH AND DEVELOPMENT OF RVSV-MARV VACCINE. |
| Jan 22, 2020 | P00003 | $0 | ADVANCED RESEARCH AND DEVELOPMENT OF RVSV-MARV VACCINE. |
| Sep 18, 2019 | P00002 | $0 | ADVANCED RESEARCH AND DEVELOPMENT OF RVSV-MARV VACCINE. |
| Mar 19, 2019 | P00001 | $0 | ADVANCED RESEARCH AND DEVELOPMENT OF RVSV-MARV VACCINE. |
| Feb 1, 2019 | 0 | $10.0M | ADVANCED RESEARCH AND DEVELOPMENT OF RVSV-MARV VACCINE. |
Estimated positioning window
Jan 31, 2028 – Jul 31, 2028
Recompete signal: . Rule-based research score; positioning dates are estimates.
50/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 50/100. Available recorded signals: 45 points.
- Contract end 2029-01-31 (822 days from calculation)
- +15 points
- 121 historical awards in this buyer and category group
- +15 points
- 27 recorded award transactions
- +10 points
- Latest award action: 2026-06-08
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +0 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-11-01 10:17:53.997580+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Nov 1, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.